Rapid Diagnostic Testing and New Antibiotics Fail to Reduce Deaths from Drug-Resistant Infections

Two major studies reveal that recent advances in diagnostics and therapeutics for drug-resistant infections (搜索)搜索该疾病 have failed to meaningfully reduce patient mortality, despite significant technological progress in both rapid testing and new antibiotic development.

Rapid Testing Shows No Survival Benefit

A multinational randomized clinical trial involving 850 patients with gram-negative bacterial blood infections across seven medical centers in four countries found that rapid antimicrobial susceptibility testing (搜索)搜索该药品 did not improve clinical outcomes compared to standard testing methods.

The study, published in JAMA, compared rapid testing conducted directly from positive blood culture bottles against standard testing on sub-cultured bacteria. While rapid testing dramatically reduced the time to availability of antimicrobial susceptibility results from approximately 44 hours to 7.5 hours, this improvement did not translate into better 30-day survival rates or other clinical outcomes.

"The analysis of clinical outcomes at day 30 revealed that the rapid antimicrobial susceptibility testing (搜索)搜索该药品 is not superior to the standard testing in achieving more desirable outcomes," the researchers reported. No significant differences were observed between groups in 30-day mortality, duration of hospital stay, intensive care unit admission, or acquisition of hospital-acquired infections.

Gram-negative bacteria, including Escherichia coli查看药品详情, are responsible for up to 50% of blood infections worldwide and are associated with high mortality rates, particularly in low- and middle-income countries where antimicrobial resistance prevalence is high.

Stewardship Benefits Without Clinical Impact

Despite the lack of survival benefit, rapid testing did demonstrate improvements in antimicrobial stewardship practices. The intervention was associated with faster antibiotic escalation or deescalation overall, more frequent guidance from antimicrobial stewardship teams, and greater acceptance of stewardship recommendations.

In patients with carbapenem-resistant infections (搜索)搜索该疾病 specifically, rapid testing showed an association with fewer patients remaining hospitalized at day 30, potentially due to faster targeted treatment. However, the trial investigators cautioned that further study is needed for more conclusive interpretation of this finding.

The researchers noted that nearly two-thirds of patients in both groups were already receiving effective antibiotic therapy at enrollment, which may have limited the ability to detect outcome differences. Additionally, some trial sites caring for patients with resistant infections did not always have access to the most effective antibiotic therapies available.

New Antibiotics Fail to Reduce Mortality

A separate large-scale US study analyzing over 8 million hospital encounters between 2016 and 2023 found that mortality rates from difficult-to-treat resistant (DTR) gram-negative infections have not improved despite the introduction of newer antibiotics.

The study identified more than 5,000 patients with confirmed DTR gram-negative infections caused by organisms such as Enterobacterales (搜索)搜索该靶点, Pseudomonas aeruginosa查看药品详情, and Acinetobacter baumannii (搜索)搜索该靶点. DTR infections are resistant to key first-line antibiotics, including β-lactams (搜索)搜索该药品 and fluoroquinolones (搜索)搜索该药品, and are associated with approximately 40% higher mortality than susceptible infections.

Use of newer DTR-active antibiotics increased during the study period, with initial prescribing rising from 4% in 2016 to 15% in 2023. However, most patients—84% even in 2023—still received initial antibiotic therapy that was not active against the infecting organism based on laboratory susceptibility testing.

Persistent Treatment Gaps

After adjusting for patient, hospital, and pandemic-related factors, researchers found no meaningful change in mortality over time for most infections caused by Enterobacterales (搜索)搜索该靶点, Pseudomonas aeruginosa查看药品详情, or Acinetobacter baumannii (搜索)搜索该靶点. The only exception was bloodstream infections (搜索)搜索该疾病 caused by Pseudomonas aeruginosa, where mortality showed a modest decline, though researchers cautioned this finding was based on a relatively small number of cases.

The persistence of in-vitro discordant therapy—where patients receive antibiotics that laboratory testing shows are ineffective against their specific infection—represents a critical clinical concern. Delays in effective treatment are known to worsen outcomes in severe infections, suggesting that simply having access to newer drugs is insufficient if they are not used promptly and appropriately.

Implications for Clinical Practice

Both studies highlight significant gaps between technological advances and clinical implementation. The rapid testing trial investigators emphasized that "reasonable access to optimal antibiotic therapies together with diagnostic innovation" is needed to improve patient outcomes.

Several institution-specific factors, including patient complexity, antimicrobial susceptibility testing (搜索)搜索该药品 methods, local pathogen prevalence, and resistance rates, can influence the effectiveness of blood culture diagnostics. The findings suggest that improving diagnostic turnaround times and antimicrobial stewardship may be as important as developing new drugs in reducing deaths from drug-resistant infections (搜索)搜索该疾病.

The researchers noted that without faster, more accurate treatment decisions, mortality rates are likely to remain high despite advances in antimicrobial therapy. Future research should focus on the cost-effectiveness of combining rapid testing with stewardship programs and strategies to improve the timely administration of appropriate antibiotics.